ABBV Jan 2025 210.000 put
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 02:01PM EDT. Market open.
| Previous Close | 45.15 |
| Open | 45.15 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 210.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 45.15 - 45.15 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
ZacksAbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
Investor's Business DailyThe Bad News Heading Into AbbVie's First-Quarter Earnings Report
AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.
ZacksEarnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
© 2024 Yahoo. All rights reserved.